The New York attorney general has launched an anti-trust investigation into Mylan Pharmaceuticals (NASDAQ:MYL) over the sale of EpiPens to local school districts.
Eric Schneiderman’s office said on Tuesday that a preliminary review showed that Mylan “may have inserted potentially anticompetitive terms into its EpiPen sales contracts with numerous local school systems”.
The company has faced criticism in recent weeks from members of Congress and Democratic presidential nominee Hillary Clinton over sharp price increases of the product that is used by sufferers of severe allergies to stave off anaphylactic shock. Read more.
Mylan shares closed up 1.1% at $40.40 on Tuesday.